TY - JOUR
T1 - Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study.
AU - Cecere, Sabrina Chiara
AU - Musacchio, Lucia
AU - Bartoletti, Michele
AU - Salutari, Vanda
AU - Arenare, Laura
AU - Lorusso, Domenica
AU - Ronzino, Graziana
AU - Lauria, Rossella
AU - Cormio, Gennaro
AU - Naglieri, Emanuele
AU - Scollo, Paolo
AU - Marchetti, Claudia
AU - Raspagliesi, Francesco
AU - Greggi, Stefano
AU - Cinieri, Saverio
AU - Bergamini, Alice
AU - Orditura, Michele
AU - Valabrega, Giorgio
AU - Scambia, Giovanni
AU - Martinelli, Fabio
AU - De Matteis, Elisabetta
AU - Cardalesi, Cinzia
AU - Loizzi, Vera
AU - Perniola, Giorgia
AU - Carella, Claudia
AU - Scandurra, Giuseppa
AU - Giannone, Gaia
AU - Pignata, Sandro
N1 - Publisher Copyright: © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/7
Y1 - 2021/7
N2 - Introduction: The role of cytoreductive surgery in the poly-ADP ribose polymerase inhibitors era is not fully investigated. We evaluated the impact of surgery performed prior to platinum-based chemotherapy followed by olaparib maintenance in platinum-sensitive BRCA-mutated recurrent ovarian cancer. Methods: This retrospective study included platinum-sensitive recurrent ovarian cancer BRCA-mutated patients from 13 Multicenter Italian Trials in Ovarian cancer and gynecological malignancies centers treated between September 2015 and May 2019. The primary outcomes were progression-free survival and overall survival. Data on post-progression treatment was also assessed. Results: Among 209 patients, 72 patients (34.5%) underwent cytoreductive surgery followed by platinum-based chemotherapy and olaparib maintenance, while 137 patients (65.5%) underwent chemotherapy treatment alone. After a median follow-up of 37.3 months (95% CI: 33.4 to 40.8), median progression-free survival in the surgery group was not reached, compared with 11 months in patients receiving chemotherapy alone (P12 months, between 6 and 12 months, and
AB - Introduction: The role of cytoreductive surgery in the poly-ADP ribose polymerase inhibitors era is not fully investigated. We evaluated the impact of surgery performed prior to platinum-based chemotherapy followed by olaparib maintenance in platinum-sensitive BRCA-mutated recurrent ovarian cancer. Methods: This retrospective study included platinum-sensitive recurrent ovarian cancer BRCA-mutated patients from 13 Multicenter Italian Trials in Ovarian cancer and gynecological malignancies centers treated between September 2015 and May 2019. The primary outcomes were progression-free survival and overall survival. Data on post-progression treatment was also assessed. Results: Among 209 patients, 72 patients (34.5%) underwent cytoreductive surgery followed by platinum-based chemotherapy and olaparib maintenance, while 137 patients (65.5%) underwent chemotherapy treatment alone. After a median follow-up of 37.3 months (95% CI: 33.4 to 40.8), median progression-free survival in the surgery group was not reached, compared with 11 months in patients receiving chemotherapy alone (P12 months, between 6 and 12 months, and
KW - cytoreduction surgical procedures
KW - ovarian cancer
U2 - 10.1136/ijgc-2020-002343
DO - 10.1136/ijgc-2020-002343
M3 - Article
SN - 1048-891X
VL - 31
SP - 1031
EP - 1036
JO - Int. J. Gynecol. Cancer
JF - Int. J. Gynecol. Cancer
IS - 7
ER -